The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10206 malaria professionals are enjoying the free benefits of MalariaWorld today

severe malaria

Not Open Access | Differential carbonylation of cytoskeletal proteins in blood group O erythrocytes: Potential role in protection against severe malaria

November 12, 2012 - 15:09 -- NOT Open Access
Author(s): 
Darío Méndez, María L. Hernáez, Ali N. Kamali, AmaliaDiez, Antonio Puyet, José M. Bautista
Reference: 
Infection, Genetics and Evolution, Volume 12, Issue 8, December 2012, Pages 1780-1787
MalariaWorld

Through redox proteomics, we detected differences in carbonylated membrane proteins among the different blood groups, both in Plasmodium-infected and uninfected erythrocytes (RBC).

Medical Condition: 

Not Open Access | Differential carbonylation of cytoskeletal proteins in blood group O erythrocytes: Potential role in protection against severe malaria

November 12, 2012 - 05:59 -- NOT Open Access
Author(s): 
Darío Méndez, María L. Hernáez, Ali N. Kamali, Amalia Diez, Antonio Puyet, José M. Bautista
Reference: 
Infection, Genetics and Evolution, Volume 12, Issue 8, December 2012, Pages 1780-1787
MalariaWorld

Our findings indicate a possible correlation between the protection against severe malaria in blood group O individuals and a specific pattern of 4-HNE-carbonylation of cytoskeleton proteins.

Not Open Access | Severe malaria, artesunate and haemolysis

July 18, 2012 - 15:13 -- Patrick Sampao
Author(s): 
Pietro Caramello, Rosanna Balbiano, Tiziano De Blasi, Monica Chiriotto, Maura Deagostini and Guido Calleri
Reference: 
J. Antimicrob. Chemother. (2012) 67(8): 2053-2054

We report the case of a 22-year-old Italian woman who presented to Amedeo di Savoia Hospital in Turin in September 2011, with fever, chills and headache after a 4 week stay in Sierra Leone, without taking malaria chemoprophylaxis.

Technology: 
Medical Condition: 
Medical Treatment: 

NOT Open Access | Effective Adjunctive Therapy by an Innate Defense Regulatory Peptide in a Preclinical Model of Severe Malaria

June 1, 2012 - 08:36 -- Patrick Sampao
Author(s): 
Ariel H. Achtman, Sandra Pilat, Louis Schofield, et al.
Reference: 
Sci Transl Med 23 May 2012: Vol. 4, Issue 135, p. 135ra64

MalariaWorldWe assessed the potential for host-directed therapy of severe malaria of a new class of anti-inflammatory drugs, the innate defense regulator (IDR) peptides, based on host defense peptides.

Medical Condition: 
Medical Treatment: 

Open Access | Clinical Study: Developing and Testing a High-Fidelity Simulation Scenario for an Uncommon Life-Threatening Disease: Severe Malaria

October 26, 2011 - 09:42 -- Patrick Sampao
Author(s): 
Andrew Kestler, Mary Kestler, Ravi Morchi, Steven Lowenstein, and Britney Anderson
Reference: 
Journal of Tropical Medicine, Volume 2011 (2011)

MalariaWorldA severe malaria sim scenario was developed based on 5 learning objectives. Sim sessions, conducted at an academic center, utilized METI ECS mannequin.

Medical Condition: 

Nitric oxide for the adjunctive treatment of severe malaria: Hypothesis and rationale

August 24, 2011 - 13:43 -- Patrick Sampao
Author(s): 
Michael Hawkes, Robert Opika Opoka, Sophie Namasopo, Christopher Miller, Andrea L. Conroy, Lena Serghides, Hani Kim, Nisha Thampi, W. Conrad Liles, Chandy C. John, Kevin C. Kain
Reference: 
Medical Hypotheses, Volume 77, Issue 3, September 2011, Pages 437-444

We hypothesize that supplemental inhaled nitric oxide (iNO) will improve outcomes in children with severe malaria receiving standard antimalarial therapy.

Medical Condition: 
Medical Treatment: 

Open Access | Methodology: Pre-referral rectal artesunate in severe malaria: a flawed trial

August 11, 2011 - 07:39 -- Patrick Sampao
Author(s): 
Karim F Hirji and Zulfiqarali G Premji
Reference: 
Trials 2011, 12:188

We performed a checklist-based and an in-depth evaluation of the trial. The evaluation criteria were based on the CONSORT statement for reporting clinical trials, the clinical trial methodology literature, and practice in malaria research.

Medical Condition: 
Medical Treatment: 

Responding to the evidence for the management of severe malaria (pages 1085–1086)

August 11, 2011 - 07:21 -- Kabogo Ndegwa
Author(s): 
Nathan P. Ford, Martin de Smet, Kavitha Kolappa and Nicholas J. White
Reference: 
Tropical Medicine & International Health, Volume 16, Issue 9, pages 1085–1086, September 2011

No abstract available

Medical Condition: 

Open Access | Study Protocol: Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: Protocol for a Randomized Controlled Trial

July 20, 2011 - 15:00 -- Patrick Sampao
Author(s): 
Michael Hawkes, Robert O Opoka, Kevin C Kain, et al.
Reference: 
Trials 2011, 12:176

This prospective, parallel arm, randomized, placebo-controlled, blinded clinical trial compares adjunctive continuous inhaled nitric oxide at 80 ppm to placebo (both arms receiving standard anti-malarial therapy), among Ugandan children aged 1-10 years of age with severe malaria.

Product: 
Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - severe malaria